A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India

• Egile Nagusiak: Ajay Prabhakar Sankhe (Egilea), Nanasaheb Somnath Memane (Egilea), Vijaykumar P. Gawali (Egilea), Sonal Nanasaheb Memane (Egilea), Ganesh Ramakrishnan (Egilea), Tapanendu Kundu (Egilea), Mayur Nimba Bagul (Egilea), Ashotosh Kumar (Egilea), Vikram Bansal (Egilea), Rashmi Tiwari (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2022-08-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Introduction: Limited treatment options exist for COVID-19 infections; thus, attempts from complementary and alternative systems (CAM) of medicine are being explored as possible therapeutic options. Ayurcov is a formulation made of ingredients mentioned in Ayurveda. These constituents have proven an...